Pages that link to "Q59391988"
Jump to navigation
Jump to search
The following pages link to A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma (Q59391988):
Displaying 50 items.
- Bisphosphonates in multiple myeloma: a network meta-analysis (Q24197839) (← links)
- Bisphosphonates in multiple myeloma (Q24236776) (← links)
- Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement (Q27011865) (← links)
- Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma (Q28081996) (← links)
- The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel (Q28362972) (← links)
- Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods (Q28364664) (← links)
- Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions (Q31048683) (← links)
- Bisphosphonates for the relief of pain secondary to bone metastases. (Q32139406) (← links)
- Bisphosphonates: from the laboratory to the clinic and back again (Q33697467) (← links)
- The biology and management of bone metastases (Q33757655) (← links)
- Rationing certainly exists in treatment for cancer (Q33800227) (← links)
- Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations (Q33809965) (← links)
- Antitumour effects of bisphosphonates: first evidence and possible mechanisms (Q33897197) (← links)
- Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). (Q33898576) (← links)
- Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies (Q33970595) (← links)
- Transdermal delivery of drugs for the treatment of bone diseases (Q34017627) (← links)
- Malignant bone pain: pathophysiology and treatments (Q34040552) (← links)
- New advances in the biology and treatment of myeloma bone disease (Q34223209) (← links)
- The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma (Q34340400) (← links)
- Novel therapeutic approaches to cancer patients with bone metastasis. (Q34460663) (← links)
- Bisphosphonates in bone diseases other than osteoporosis. (Q34540323) (← links)
- Strategies for management of prostate cancer-related bone pain (Q34558618) (← links)
- Bone disease in myeloma (Q34678320) (← links)
- What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates (Q34787778) (← links)
- Bisphosphonate therapy in multiple myeloma: past, present, future (Q35013342) (← links)
- Effectiveness and cost of bisphosphonate therapy in tumor bone disease (Q35053969) (← links)
- Myeloma: Update on supportive care strategies (Q35116240) (← links)
- Aetiology of bone disease and the role of bisphosphonates in multiple myeloma (Q35121710) (← links)
- Management of multiple myeloma: a systematic review and critical appraisal of published studies (Q35121715) (← links)
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial (Q35141814) (← links)
- Bisphosphonates and radiation therapy for palliation of metastatic bone disease (Q35202905) (← links)
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer (Q35208717) (← links)
- The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future (Q35584866) (← links)
- New insights into the pathophysiology and management of bone disease in multiple myeloma (Q35591086) (← links)
- A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma (Q35870578) (← links)
- Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma (Q35981530) (← links)
- Management of paraproteinaemia (Q36778432) (← links)
- Bisphosphonates and osteonecrosis of the jaws: science and rationale (Q36797579) (← links)
- The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma (Q36870585) (← links)
- Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid (Q36908470) (← links)
- International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease (Q36929923) (← links)
- Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012 (Q37057028) (← links)
- A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease (Q37185494) (← links)
- The effect of risedronate on posterior lateral spinal fusion in a rat model (Q37312942) (← links)
- Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer (Q37355362) (← links)
- Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases (Q37403207) (← links)
- Clodronic acid formulations available in Europe and their use in osteoporosis: a review (Q37477158) (← links)
- Therapeutic Options in the Management of Myeloma Bone Disease (Q37777489) (← links)
- The use of bisphosphonates in cancer treatment (Q37800183) (← links)
- Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates (Q37830052) (← links)